| General Information |
| Business: |
(Incorporated in Delaware)
We are a clinical oncology company developing radiopharmaceuticals to treat solid tumors.
Our lead drug candidates are:
-Ac-AKY-1189 to treat cancers that express Nectin-4 – We are now enrolling 150 patients in a Phase 1B trials with preliminary results expected in the first quarter of 2027, and
–Ac-AKY-2519 to treat tumors that express B7-H3 – We plan to submit an IND filing in 2026.
Note: Net loss and revenue are for the 12 months that ended Sept. 30, 2025.
(Note: Aktis Oncology filed its S-1 for its IPO on Dec. 19, 2025, without disclosing the terms. Estimated proceeds are $100 million, a placeholder figure.)
|
| Industry: |
Pharmaceuticals |
| Employees: |
|
| Founded: |
2020 |
| Contact Information |
| Address |
17 Drydock Avenue, Suite 17-401 Boston, Massachusetts 02210 |
| Phone Number |
(617) 461-4023 |
| Web Address |
|
| View Prospectus: |
Aktis Oncology |
| Financial Information |
| Market Cap |
|
| Revenues |
$6.0 mil (last 12 months) |
| Net Income |
$-60.65 mil (last 12 months) |
| IPO Profile |
| Symbol |
AKTS |
| Exchange |
NASDAQ |
| Shares (millions): |
0.0 |
| Price range |
$0.00 - $0.00 |
| Est. $ Volume |
$100.0 mil |
| Manager / Joint Managers |
J.P.Morgan/BofA Securities/Leerink Partners/TD Cowen |
| CO-Managers |
|
| Expected To Trade: |
|
|
Status:
|
TBA |
| Quiet Period Expiration Date: |
Available only to Subscribers |
| Lock-Up Period Expiration Date: |
Available only to Subscribers |
| SCOOP Rating |
Available only to Subscribers |
| Rating Change |
Available only to Subscribers |
